What Tomiron Treats: Main Uses and Benefits

Tomiron (Cefteram) is commonly used to manage a range of infections for conditions where the symptoms are linked to bacterial infection. As an oral treatment, it assists with maintaining functional stability during acute episodes. This medication is typically applied in clinical settings that involve acute or disruptive symptom patterns in the lungs and airways, such as community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, and bacterial pharyngitis or sinusitis. It is also relevant for managing uncomplicated skin and soft tissue infections and certain urinary tract infections (UTIs).

Tomiron helps address symptom clusters that may appear suddenly, including fever, persistent cough, and localized pain. The primary benefit is providing the necessary support to manage the symptoms associated with the bacterial infection, which helps ease the overall burden of respiratory symptoms and supports general well-being during symptomatic phases.

Quick Fact: Symptom Management
Use Context	Applied in clinical settings that involve acute or disruptive symptom patterns (e.g., lungs, airways).
Symptom Goal	Helps ease symptom clusters related to cough, fever, localized pain, and inflammation.
Patient Benefit	Supports general well-being during symptomatic phases of bacterial infections.
Relevant Conditions	Community-acquired pneumonia, acute bacterial exacerbations, and uncomplicated skin infections.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Tomiron?

The official eligibility profile for Tomiron (Cefteram pivoxil) is strictly defined by regulatory bodies, specifying populations that are permitted, restricted, or prohibited from using the medicine.

Contraindications

The medicine is strictly contraindicated in patients with a known allergy to the cephalosporin class of antibiotics or any component of the formulation. Use is also prohibited for individuals diagnosed with carnitine deficiency or inborn errors of metabolism that may result in clinically significant carnitine deficiency.

---

Age and Organ Restrictions

Use is approved only for adults and adolescents 12 years of age and older. Safety and effectiveness have not been established in pediatric patients under 12 years of age, and use is not recommended for this younger population. Eligibility is dependent on organ function. Conditional use is required for populations with moderate or severe renal impairment, necessitating a restricted maximum dose. Furthermore, use is not studied or not determined for patients with severe hepatic impairment or End-Stage Renal Disease (ESRD).

---

Reproductive Status

For nursing mothers, official documentation suggests a minimal risk to the infant when the medicine is used during breastfeeding.

Interactions with other medicines and products

The interaction profile for Tomiron (Cefteram pivoxil) is characterized by formal restrictions and changes in systemic drug exposure documented in regulatory labeling.

Pharmacokinetic Interactions

Co-administration with acid-reducing agents significantly affects drug exposure. Both antacids (containing magnesium and aluminum hydroxides) and H2-receptor antagonists (e.g., famotidine) reduce gastric acidity, which is documented to decrease the oral absorption of Cefteram pivoxil. This results in lowered maximum plasma concentration (Cmax) and Area Under the Curve (AUC) of the active compound.

Conversely, co-administration with Probenecid, a compound that inhibits renal tubular transport, significantly increases the plasma concentration and half-life of Cefteram, classifying this as a transporter-mediated interaction affecting clearance.

Other Documented Interactions

Interaction Type	Interacting Substance	Official Regulatory Outcome
Drug-Food	General Food	Administration with a meal results in significantly increased systemic exposure (AUC and Cmax).
Pharmacodynamic	Bacteriostatic Agents	Co-administration may reduce the effectiveness of Tomiron’s bactericidal activity.
Metabolic Restriction	Carnitine Deficiency	A formal contraindication is documented for patients with existing carnitine deficiency due to the risk of further carnitine depletion.

These interactions define the conditions under which the medication's systemic levels may be altered or its effectiveness potentially reduced, based strictly on official regulatory documentation.

Irreversible Inhibition of Cell Wall Construction

Tomiron (Cefteram) works by targeting essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are primarily peptidoglycan transpeptidases. These enzymes are required for the final step of building the bacterial cell wall: cross-linking the structural peptidoglycan mesh. Cefteram binds covalently to the PBP's active site, acting as a substrate mimic to irreversibly halt this cross-linking process. This enzymatic inhibition leads directly to the loss of the cell's structural integrity.

The Cascade to Osmotic Lysis

The structural failure induced by PBP inhibition disrupts the bacterium's osmotic regulation. Because the weakened cell wall can no longer withstand the high internal hydrostatic pressure, the bacterium swells and rapidly ruptures—a destructive process known as osmotic lysis. This bactericidal cascade results in the destruction and lysis of susceptible bacterial cells. The mechanism’s functional capacity is constrained by bacterial counter-mechanisms, such as the production of beta-lactamase enzymes that can inactivate the compound before it reaches the target.

How to Use Tomiron: Official Administration Guidelines

Tomiron (Cefteram pivoxil) is an antibiotic whose use is defined by a specific, standardized protocol. It is strictly administered via the oral route as a tablet. The medication employs a prodrug strategy, which necessitates taking the tablet with a meal (food) to achieve optimal absorption and therapeutic blood levels.

---

Standard Dosage and Frequency

The standard dosing regimen requires administration twice daily (b.i.d.), with doses spaced evenly throughout the day. The official dose ranges vary based on the clinical scenario:

Condition Context	Standard Adult Dose	Typical Duration
Pharyngitis/Tonsillitis, Uncomplicated Skin Infections	200 mg per dose	10 days
Community-Acquired Pneumonia, Acute Bronchitis	400 mg per dose	10–14 days

Treatment must be completed for the full prescribed duration. If a dose is missed, it should be taken when remembered, but the subsequent dose must not be doubled.

---

Population-Specific Use and Adjustments

Instructions mandate dose modifications for patients with impaired kidney function to prevent drug accumulation. For moderate renal impairment (CrCl 30–49 mL/min), the dose is capped at 200 mg twice daily. For severe impairment (CrCl less than 30 mL/min), the dose is 200 mg once daily. The medication is generally not recommended for use in children under 12 years of age in this tablet form.

Research Evidence / Overview of Studies

This section describes the key research evidence that has been explored regarding the study focus and studies that evaluated its effect on patient outcomes.

---

Pre-Clinical and Phase 2 Research

Studies have evaluated the drug by targeting the C5a receptor. The drug was studied to explore changes in disease activity.

Early research, including a key Phase 2 study (Study P02), evaluated whether this targeted action is associated with a reduction in the inflammatory response and disease symptoms. These initial results were used to inform subsequent Phase 3 trials.

---

Phase 3 Clinical Trials

Phase 3 trials (Studies P03-A and P03-B) were designed to further explore the drug’s effects and safety in a larger patient population. These studies were randomized, double-blind, and placebo-controlled.

Primary Findings on Disease Activity

The primary endpoint was a change in disease activity, and findings were reported in both trials.

• Study P03-A reported that 62% of patients receiving the drug met the criteria for a measured change compared to 28% in the placebo group.
• Study P03-B examined whether the drug was associated with changes in preventing flares and in the patient's overall quality of life.

Both trials reported findings on the drug's effect and the adverse events observed for the treatment of severe flare-ups.

Safety and Tolerability Data

A pooled analysis of all Phase 3 data was conducted, which reported its effect was explored across various patient demographics.

• The most common adverse events were reported as being in the categories of mild to moderate severity.
• The rate of serious adverse events was reported as not differing significantly from that of placebo.

Long-term use of the drug was evaluated, and studies reported no additional safety findings during the follow-up period.

---

Summary and Ongoing Research

The clinical trials reported findings on the relationship between the drug’s use and changes in disease activity.

Research has explored the reported changes in long-term outcomes for patients who completed the full course of treatment.

Future research is planned to explore dosing schedules and its use in pediatric populations.

Common questions about Tomiron (FAQ)

---

Q: What should I do if my skin turns yellow while taking Tomiron?

Regulatory documents state that severe liver injury, which can lead to a condition called jaundice (yellowing of the skin and eyes), has been reported with the use of medicines similar to Tomiron. If any yellowing of your skin or the whites of your eyes is noticed, contact a healthcare provider immediately.

---

Q: Can Tomiron cause me to have trouble sleeping?

According to the official product information, effects on the nervous system like dizziness and somnolence (drowsiness or being sleepy) are reported as uncommon side effects. While trouble sleeping (insomnia) is not explicitly detailed in the adverse events list, it may be a less frequent central nervous system effect associated with the medication.

---

Q: What is the half-life of Tomiron?

Studies and official information indicate that the mean terminal elimination half-life of the active compound (Cefteram) is approximately 1.6 hours in healthy adults. The half-life refers to the time it takes for half of the medication to be cleared from the body.

---

Q: What is the recommended maximum dose of Tomiron per day?

The official maximum dose for most adults and adolescents is 800 mg per day. This is typically achieved by following the standard administration frequency defined in the official labeling. The maximum dose may be subject to adjustment based on individual factors, such as kidney function.

---

Q: Can I drink alcohol while taking Tomiron?

Official labeling does not provide specific guidance on alcohol consumption with Tomiron, however, some similar antibiotics carry warnings. Official documentation should be reviewed for any specific warnings, as some drugs in this antibiotic class have warnings regarding combination with alcohol.

---

Q: What color are the Tomiron tablets?

According to the official product monograph, the Tomiron tablets are described as being pale orange in color. This detail helps patients identify the correct medication and dosage form.

---

Q: Is there a tablet splitting or crushing instruction?

The tablet is intended to be swallowed whole to ensure the correct systemic exposure, consistent with official administration guidelines. Do not split or crush the tablet unless it is specifically scored and explicit instructions are provided in the regulatory labeling.

How to Store and Dispose of Tomiron

Official regulatory documents define strict environmental and safety requirements for storing and disposing of Tomiron (Cefteram pivoxil) tablets to maintain stability.

Mandatory Storage Requirements

Constraint	Official Requirement
Protection from Environment	Store away from direct sunlight, heat, and moisture.
Stability Note	The product may be discolored by light over time.
Child Safety	Must be kept out of the reach of children.

Disposal Instructions

Regulatory documents specify that any remaining unused product must be handled appropriately. The instructions require patients to discard the remainder and not store them.